Trial Profile
Monitoring EGFR mutation status with cell-free DNA: a prospective exploratory analyses of phase Ib study of osimertinib plus ramucirumab in lung adenocarcinoma patients with EGFR T790M mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Oct 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2021 Results published in the Anticancer Research
- 11 Aug 2020 Planned End Date changed from 30 Jun 2020 to 30 Sep 2021.
- 04 Dec 2019 Status changed from recruiting to active, no longer recruiting.